Loxo Oncology, Inc. (NASDAQ:LOXO) Insider Naarden Jacob Van Sells 3,082 Shares

Loxo Oncology, Inc. (NASDAQ:LOXO) insider Naarden Jacob Van sold 3,082 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $81.19, for a total transaction of $250,227.58. Following the completion of the sale, the insider now directly owns 1,541 shares of the company’s stock, valued at $125,113.79. The transaction was disclosed in a filing with the SEC, which is available at this link.

Naarden Jacob Van also recently made the following trade(s):

  • On Tuesday, November 28th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The shares were sold at an average price of $74.50, for a total transaction of $229,609.00.
  • On Tuesday, October 31st, Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock. The stock was sold at an average price of $86.52, for a total value of $133,327.32.
  • On Tuesday, September 19th, Naarden Jacob Van sold 3,082 shares of Loxo Oncology stock. The stock was sold at an average price of $89.00, for a total value of $274,298.00.

Loxo Oncology, Inc. (NASDAQ:LOXO) traded up $2.43 during trading on Thursday, hitting $88.86. The company had a trading volume of 316,700 shares, compared to its average volume of 287,882. Loxo Oncology, Inc. has a 12-month low of $36.75 and a 12-month high of $95.92. The firm has a market capitalization of $2,650.00, a P/E ratio of -15.29 and a beta of 2.54.

A number of large investors have recently made changes to their positions in the business. FMR LLC lifted its holdings in Loxo Oncology by 12.1% in the second quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock valued at $352,420,000 after acquiring an additional 472,814 shares during the period. BlackRock Inc. raised its stake in shares of Loxo Oncology by 20.6% during the 2nd quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after buying an additional 273,291 shares during the period. Alliancebernstein L.P. raised its stake in shares of Loxo Oncology by 50.2% during the 2nd quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after buying an additional 312,988 shares during the period. Vanguard Group Inc. raised its stake in shares of Loxo Oncology by 24.7% during the 2nd quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock worth $73,351,000 after buying an additional 181,471 shares during the period. Finally, Lord Abbett & CO. LLC raised its stake in shares of Loxo Oncology by 372.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock worth $59,304,000 after buying an additional 582,862 shares during the period. 99.98% of the stock is owned by institutional investors.

Several research firms have recently weighed in on LOXO. BTIG Research reiterated a “buy” rating and set a $102.00 target price (up from $75.00) on shares of Loxo Oncology in a research report on Friday, September 29th. Cowen restated a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 target price (up previously from $95.00) on shares of Loxo Oncology in a research note on Friday, October 6th. BidaskClub upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $90.57.

WARNING: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/naarden-jacob-van-sells-3082-shares-of-loxo-oncology-inc-loxo-stock.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply